An international external quality assessment for laboratory diagnosis of heparin-induced thrombocytopenia.


Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
03 2019
Historique:
received: 26 09 2018
pubmed: 15 1 2019
medline: 9 4 2020
entrez: 15 1 2019
Statut: ppublish

Résumé

Essentials A pilot study for External Quality Assessment for testing of HIT is described. The qualitative accordance for the PF4/heparin IgG test was 97.6%. The qualitative accordance for functional HIT tests was considerably lower. External Quality Assessment for functional HIT tests is required. SUMMARY: Objective Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening complication of heparin exposure. Diagnosis is most reliable using a combination of an enzyme immunoassay (EIA) that detects antibodies against platelet factor 4 (PF4)/heparin complexes ("antigen" assay) and a "functional" assay that detects platelet-activating properties of the pathogenic HIT antibodies. No External Quality Assessment (EQA) is available for a combination of the tests. Here we report on the results of the first international EQA. Methods The pilot EQA was organized by the Department of Transfusion Medicine, Universitätsmedizin Greifswald, Germany. Six serum samples of patients, which were referred to Greifswald for HIT diagnosis, and one negative control sample were distributed to seven participants in Germany, Canada, and Singapore. Participants were asked to report the optical density (OD) values of their local EIA test for IgG-specific antibodies against the PF4/heparin complexes and the results for a functional assay (HIPA or SRA). Consensus was defined as a minimum 70% agreement, i.e., agreement among at least five of the seven participating laboratories. Results and conclusion Six out of seven participants reported results for EIA, with a high quantitative accordance (97.6%). For the functional assay, consensus was reached for all samples except the negative control, for which some participants reported nonspecific reactivity. All HIT-negative samples were correctly diagnosed by all participants; for HIT-positive samples, consensus of 70% was reached. Although the limited availability of sample material is an obstacle to overcome, an EQA combining both EIA and functional testing is feasible.

Identifiants

pubmed: 30640980
doi: 10.1111/jth.14383
pii: S1538-7836(22)02832-X
doi:

Substances chimiques

Antibodies 0
Anticoagulants 0
Biomarkers 0
Immunoglobulin G 0
PF4 protein, human 0
Platelet Factor 4 37270-94-3
Heparin 9005-49-6

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

525-531

Informations de copyright

© 2019 International Society on Thrombosis and Haemostasis.

Auteurs

Julia J M Eekels (JJM)

Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany.

Karina Althaus (K)

Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany.
Transfusion Medicine, Medical Faculty of Tübingen, Tübingen, Germany.

Tamam Bakchoul (T)

Transfusion Medicine, Medical Faculty of Tübingen, Tübingen, Germany.

Hartmut Kroll (H)

Institute for Transfusion Medicine Dessau, Red Cross Blood Transfusion Service NSTOB, Dessau, Germany.

Volker Kiefel (V)

Institut für Transfusionsmedizin, Universitätsmedizin Rostock, Rostock, Germany.

Ishac Nazy (I)

Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.

Lau Soon Lee (LS)

Department of Laboratory Medicine, Tan Tock Seng Hospital, Singapore, Singapore.

Ulrich Sachs (U)

Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany.

Theodore E Warkentin (TE)

Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany.
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.

Andreas Greinacher (A)

Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH